These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

387 related articles for article (PubMed ID: 18829501)

  • 1. N-(2,6-dimethoxypyridine-3-yl)-9-methylcarbazole-3-sulfonamide as a novel tubulin ligand against human cancer.
    Wang YM; Hu LX; Liu ZM; You XF; Zhang SH; Qu JR; Li ZR; Li Y; Kong WJ; He HW; Shao RG; Zhang LR; Peng ZG; Boykin DW; Jiang JD
    Clin Cancer Res; 2008 Oct; 14(19):6218-27. PubMed ID: 18829501
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel oral indoline-sulfonamide agent, N-[1-(4-methoxybenzenesulfonyl)-2,3-dihydro-1H-indol-7-yl]-isonicotinamide (J30), exhibits potent activity against human cancer cells in vitro and in vivo through the disruption of microtubule.
    Liou JP; Hsu KS; Kuo CC; Chang CY; Chang JY
    J Pharmacol Exp Ther; 2007 Oct; 323(1):398-405. PubMed ID: 17660383
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BPR0L075, a novel synthetic indole compound with antimitotic activity in human cancer cells, exerts effective antitumoral activity in vivo.
    Kuo CC; Hsieh HP; Pan WY; Chen CP; Liou JP; Lee SJ; Chang YL; Chen LT; Chen CT; Chang JY
    Cancer Res; 2004 Jul; 64(13):4621-8. PubMed ID: 15231674
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Double blockade of cell cycle at g(1)-s transition and m phase by 3-iodoacetamido benzoyl ethyl ester, a new type of tubulin ligand.
    Jiang JD; Denner L; Ling YH; Li JN; Davis A; Wang Y; Li Y; Roboz J; Wang LG; Perez-Soler R; Marcelli M; Bekesi G; Holland JF
    Cancer Res; 2002 Nov; 62(21):6080-8. PubMed ID: 12414632
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis and structure-activity relationships of carbazole sulfonamides as a novel class of antimitotic agents against solid tumors.
    Hu L; Li ZR; Li Y; Qu J; Ling YH; Jiang JD; Boykin DW
    J Med Chem; 2006 Oct; 49(21):6273-82. PubMed ID: 17034133
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Voreloxin, formerly SNS-595, has potent activity against a broad panel of cancer cell lines and in vivo tumor models.
    Hoch U; Lynch J; Sato Y; Kashimoto S; Kajikawa F; Furutani Y; Silverman JA
    Cancer Chemother Pharmacol; 2009 Jun; 64(1):53-65. PubMed ID: 18931998
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pseudolaric acid B, a novel microtubule-destabilizing agent that circumvents multidrug resistance phenotype and exhibits antitumor activity in vivo.
    Wong VK; Chiu P; Chung SS; Chow LM; Zhao YZ; Yang BB; Ko BC
    Clin Cancer Res; 2005 Aug; 11(16):6002-11. PubMed ID: 16115945
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vivo tumor growth inhibition produced by a novel sulfonamide, E7010, against rodent and human tumors.
    Koyanagi N; Nagasu T; Fujita F; Watanabe T; Tsukahara K; Funahashi Y; Fujita M; Taguchi T; Yoshino H; Kitoh K
    Cancer Res; 1994 Apr; 54(7):1702-6. PubMed ID: 8137285
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel pyridinyl and pyrimidinylcarbazole sulfonamides as antiproliferative agents.
    Hu L; Li ZR; Wang YM; Wu Y; Jiang JD; Boykin DW
    Bioorg Med Chem Lett; 2007 Mar; 17(5):1193-6. PubMed ID: 17197178
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The synthetic compound CC-5079 is a potent inhibitor of tubulin polymerization and tumor necrosis factor-alpha production with antitumor activity.
    Zhang LH; Wu L; Raymon HK; Chen RS; Corral L; Shirley MA; Narla RK; Gamez J; Muller GW; Stirling DI; Bartlett JB; Schafer PH; Payvandi F
    Cancer Res; 2006 Jan; 66(2):951-9. PubMed ID: 16424030
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tricyclic pyrone analogs: a new synthetic class of bifunctional anticancer drugs that inhibit nucleoside transport, microtubule assembly, the viability of leukemic cells in vitro and the growth of solid tumors in vivo.
    Perchellet EM; Ladesich JB; Magill MJ; Chen Y; Hua DH; Perchellet JP
    Anticancer Drugs; 1999 Jun; 10(5):489-504. PubMed ID: 10477169
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preclinical efficacy spectrum and pharmacokinetics of ixabepilone.
    Lee FY; Smykla R; Johnston K; Menard K; McGlinchey K; Peterson RW; Wiebesiek A; Vite G; Fairchild CR; Kramer R
    Cancer Chemother Pharmacol; 2009 Jan; 63(2):201-12. PubMed ID: 18350296
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quinolone analogue inhibits tubulin polymerization and induces apoptosis via Cdk1-involved signaling pathways.
    Chen YC; Lu PH; Pan SL; Teng CM; Kuo SC; Lin TP; Ho YF; Huang YC; Guh JH
    Biochem Pharmacol; 2007 Jun; 74(1):10-9. PubMed ID: 17475221
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mechanism of action of E7010, an orally active sulfonamide antitumor agent: inhibition of mitosis by binding to the colchicine site of tubulin.
    Yoshimatsu K; Yamaguchi A; Yoshino H; Koyanagi N; Kitoh K
    Cancer Res; 1997 Aug; 57(15):3208-13. PubMed ID: 9242451
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TTI-237: a novel microtubule-active compound with in vivo antitumor activity.
    Beyer CF; Zhang N; Hernandez R; Vitale D; Lucas J; Nguyen T; Discafani C; Ayral-Kaloustian S; Gibbons JJ
    Cancer Res; 2008 Apr; 68(7):2292-300. PubMed ID: 18381436
    [TBL] [Abstract][Full Text] [Related]  

  • 16. STX140 is efficacious in vitro and in vivo in taxane-resistant breast carcinoma cells.
    Newman SP; Foster PA; Stengel C; Day JM; Ho YT; Judde JG; Lassalle M; Prevost G; Leese MP; Potter BV; Reed MJ; Purohit A
    Clin Cancer Res; 2008 Jan; 14(2):597-606. PubMed ID: 18223236
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Benzoylurea derivatives as a novel class of antimitotic agents: synthesis, anticancer activity, and structure-activity relationships.
    Song DQ; Wang Y; Wu LZ; Yang P; Wang YM; Gao LM; Li Y; Qu JR; Wang YH; Li YH; Du NN; Han YX; Zhang ZP; Jiang JD
    J Med Chem; 2008 Jun; 51(11):3094-103. PubMed ID: 18457382
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biological evaluation on different human cancer cell lines of novel colchicine analogs.
    De Vincenzo R; Ferlini C; Distefano M; Gaggini C; Riva A; Bombardelli E; Morazzoni P; Danieli B; Capelli G; Mancuso S; Scambia G
    Oncol Res; 1999; 11(3):145-52. PubMed ID: 10527074
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetic profile of the microtubule stabilizer patupilone in tumor-bearing rodents and comparison of anti-cancer activity with other MTS in vitro and in vivo.
    O'Reilly T; Wartmann M; Brueggen J; Allegrini PR; Floersheimer A; Maira M; McSheehy PM
    Cancer Chemother Pharmacol; 2008 Nov; 62(6):1045-54. PubMed ID: 18301895
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MPC-6827: a small-molecule inhibitor of microtubule formation that is not a substrate for multidrug resistance pumps.
    Kasibhatla S; Baichwal V; Cai SX; Roth B; Skvortsova I; Skvortsov S; Lukas P; English NM; Sirisoma N; Drewe J; Pervin A; Tseng B; Carlson RO; Pleiman CM
    Cancer Res; 2007 Jun; 67(12):5865-71. PubMed ID: 17575155
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.